XKRX000227
Market cap54mUSD
Jan 10, Last price
9,770.00KRW
1D
0.00%
1Q
-6.33%
Jan 2017
54.66%
Name
Yuyu Pharma Inc
Chart & Performance
P/E
—
P/S
1.15
EPS
—
Div Yield, %
1.27%
Shrs. gr., 5y
2.64%
Rev. gr., 5y
10.55%
Revenues
137.21b
-1.20%
Net income
-7.18b
L+62.27%
CFO
421m
P
Dividend
Dec 27, 2023110 KRW/sh
Profile
Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, including osteoporosis, brainbone metabolism-hypocalcemia improvement, cerebral and peripheral circulatory disturbance, tromboembolism, respiratory organ, hypertension, pulmonary tuberculosis therapy, arthrifuge, diabetic neuropathy therapy, eczematous dermatitis drugs, and other circulatory system drugs, as well as antibiotics and skeletal muscle relaxants. It also provides non-prescription drugs and health supplements. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Seoul, South Korea.
IPO date
Nov 18, 1975
Employees
Domiciled in
KR
Incorporated in
KR
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑03 | 2016‑03 | 2015‑03 | |
| Income | ||||||||||
Revenues | 137,209,589 -1.20% | 138,881,056 20.08% | ||||||||
Cost of revenue | 111,768,970 | 114,181,801 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 25,440,618 | 24,699,256 | ||||||||
NOPBT Margin | 18.54% | 17.78% | ||||||||
Operating Taxes | 98,436 | 615,016 | ||||||||
Tax Rate | 0.39% | 2.49% | ||||||||
NOPAT | 25,342,182 | 24,084,239 | ||||||||
Net income | (7,180,900) 62.27% | (4,425,393) 380.87% | ||||||||
Dividends | (2,001,735) | (2,033,747) | ||||||||
Dividend yield | 2.33% | 1.97% | ||||||||
Proceeds from repurchase of equity | (1,785,236) | |||||||||
BB yield | 1.73% | |||||||||
| Debt | ||||||||||
Debt current | 25,386,189 | 37,424,958 | ||||||||
Long-term debt | 14,857,429 | 2,645,227 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 9,501,573 | 1,973,690 | ||||||||
Net debt | 1,022,201 | 8,287,806 | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | 420,857 | (6,229,001) | ||||||||
CAPEX | (4,514,389) | (5,567,721) | ||||||||
Cash from investing activities | (2,814,814) | (8,543,848) | ||||||||
Cash from financing activities | 7,160,246 | (9,083,180) | ||||||||
FCF | 18,772,143 | 13,401,797 | ||||||||
| Balance | ||||||||||
Cash | 32,354,182 | 30,777,637 | ||||||||
Long term investments | 6,867,235 | 1,004,741 | ||||||||
Excess cash | 32,360,938 | 24,838,325 | ||||||||
Stockholders' equity | 54,847,380 | 81,951,386 | ||||||||
Invested Capital | 136,903,443 | 139,270,382 | ||||||||
ROIC | 18.35% | 18.86% | ||||||||
ROCE | 14.65% | 14.72% | ||||||||
| EV | ||||||||||
Common stock shares outstanding | 16,268 | 16,581 | ||||||||
Price | 5,280.00 -15.11% | 6,220.00 -20.36% | ||||||||
Market cap | 85,894,781 -16.71% | 103,131,973 -17.26% | ||||||||
EV | 97,677,498 | 120,570,098 | ||||||||
EBITDA | 31,047,951 | 29,726,634 | ||||||||
EV/EBITDA | 3.15 | 4.06 | ||||||||
Interest | 2,553,778 | 2,580,742 | ||||||||
Interest/NOPBT | 10.04% | 10.45% | ||||||||